Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma

被引:4
|
作者
Hsu, Wei-Fan [1 ,2 ,3 ,9 ]
Chang, Kai-Chih [1 ]
Chen, Te-Hong [4 ,9 ]
Lin, Chien-Hung [5 ,9 ]
Lin, Ying-Chun [6 ,9 ]
Tsai, Ming-Hung [7 ,9 ]
Chen, Pei-Yu [8 ,9 ]
Wang, Hung-Wei [1 ,3 ,9 ]
Chu, Chia-Sheng [1 ,9 ]
Peng, Cheng-Yuan [1 ,3 ,9 ]
机构
[1] China Med Univ Hosp, Ctr Digest Med, Dept Internal Med, 2 Der Yuh Rd, Taichung 40447, Taiwan
[2] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan
[3] China Med Univ, Sch Med, Taichung, Taiwan
[4] China Med Univ Hosp, Dept Surg, Taichung, Taiwan
[5] China Med Univ Hosp, Dept Radiol, Taichung, Taiwan
[6] China Med Univ Hosp, Dept Radiat Oncol, Taichung, Taiwan
[7] China Med Univ Hosp, Div Hematol & Oncol, Dept Internal Med, Taichung, Taiwan
[8] China Med Univ Hosp, Dept Pathol, Taichung, Taiwan
[9] China Med Univ Hosp, Liver Canc Team, Taichung, Taiwan
关键词
albumin-bilirubin (ALBI) grade; intermediate-stage hepatocellular carcinoma; Lok grade; noninvasive model; SIGNIFICANT FIBROSIS; LIVER-FUNCTION; HEPATITIS-B; CIRRHOSIS; INDEX; ALBI; SUBCLASSIFICATION; CRITERIA; PROPOSAL; DISEASE;
D O I
10.1097/MD.0000000000027000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intermediate-stage hepatocellular carcinoma (HCC) is heterogeneous in terms of tumor size, number, and effects on liver function. Various noninvasive models have been proposed to assess functional hepatic reserve or fibrosis severity in patients with HCC. This study assessed the feasibility of 10 noninvasive models and compared their prognostic ability for patients with intermediate-stage HCC. This study retrospectively enrolled 493 patients with intermediate-stage HCC who received treatment at China Medical University Hospital from January 2012 to November 2018. Demographic data, clinical features, and factors associated with overall survival (OS) were recorded at baseline. Receiver-operating characteristic curve analysis and the DeLong method were respectively employed to evaluate and compare the models' OS prediction performance. Of the 493 patients, 373 (75.7%) were male, and 275 (55.8%) had liver cirrhosis (LC). The median age was 64 years (interquartile range: 55-72). Most patients had tumor volume <= 50% (n = 424, 86.0%), and the maximum tumor size was 6.0 (4.0-8.5) cm. The median alpha-fetoprotein was 36.25 (6.13-552.91) ng/mL. The patients underwent transarterial chemoembolization (TACE, n = 349) or surgery (n = 144). The median follow-up period was 26.07 (9.77-48.27) months. Across the 10 models, the albumin-bilirubin (ALBI) score had the highest area under the receiver operating characteristic curve (AUROC) (0.644, 95% confidence interval: 0.595-0.693) in all patients. In subgroup analyses, the Lok index, platelet-albumin-bilirubin score, ALBI score, and Lok index had the highest AUROC values in patients without cirrhosis, with cirrhosis, undergoing TACE, and undergoing surgery, respectively. Multivariate Cox regression analysis revealed that independent predictors of longer OS were ALBI grade 1 in all patients, patients with LC, and patients undergoing TACE and Lok index grade 1 in patients without LC and patients undergoing surgery. Among the 10 noninvasive models, ALBI score exhibited the highest diagnostic value in predicting OS for all patients, patients with cirrhosis, and those undergoing TACE, and Lok index grade exhibited the highest diagnostic value in predicting OS in patients without cirrhosis and those undergoing surgery.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] COMPARISON OF NONINVASIVE MODELS FOR PREDICTING THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA OR HEPATIC DECOMPENSATION
    Park, Hana
    Jung, Eun Suk
    Jung, Kyu Sik
    Choi, Eun Hee
    Ahn, Sang Hoon
    Kim, Do Young
    Park, Jun Yong
    Han, Kwang-Hyub
    Chon, Chae Yoon
    Kim, Seung Up
    HEPATOLOGY, 2011, 54 : 1231A - 1231A
  • [42] Prognostic significance of nodular number in patients undergoing hepatectomy of intermediate-stage hepatocellular carcinoma
    Fan, Zhong-Qi
    Serenari, Matteo
    Lv, Xing
    Schwartz, Myron
    Qiu, Wei
    Pawlik, Timothy M.
    Chen, Zhong
    Zhou, Ya-Hao
    Wang, Xian-Ming
    Chen, Ting-Hao
    Li, Jie
    Zhang, Cheng-Wu
    Wang, Hong
    Zhang, Yao-Ming
    Gu, Wei-Min
    Liang, Ying-Jian
    Diao, Yong-Kang
    Yao, Lan-Qing
    Li, Chao
    Cescon, Matteo
    Wang, Ming-Da
    Sun, Xiao-Dong
    Lau, Wan Yee
    Shen, Feng
    Yang, Tian
    Lv, Guoyue
    BRITISH JOURNAL OF SURGERY, 2024, 111 (03)
  • [43] Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma
    Arizumi, Tadaaki
    Ueshima, Kazuomi
    Iwanishi, Mina
    Minami, Tomohiro
    Chishina, Hirokazu
    Kono, Masashi
    Takita, Masahiro
    Kitai, Satoshi
    Inoue, Tatsuo
    Yada, Norihisa
    Hagiwara, Satoru
    Ida, Hiroshi
    Minami, Yasunori
    Sakurai, Toshiharu
    Kitano, Masayuki
    Nishida, Naoshi
    Kudo, Masatoshi
    ONCOLOGY, 2015, 89 : 47 - 52
  • [44] Efficacy and safety of hepatic arterial infusion chemotherapy in patients with intermediate-stage hepatocellular carcinoma
    Yamashita, Tatsuya
    Terashima, Takeshi
    Takata, Noboru
    Horii, Rika
    Sunagozaka, Hajime
    Arai, Kuniaki
    Kaneko, Shuichi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 411 - 411
  • [45] A prospective observational study of lenvatinib as an initial treatment for patients with intermediate-stage hepatocellular carcinoma
    Kobayashi, Satoshi
    Numata, Kazushi
    Fukushima, Taito
    Ueno, Makoto
    Moriya, Satoshi
    Chuma, Makoto
    Tsuruya, Kota
    Hirose, Shunji
    Kagawa, Tatehiro
    Hattori, Nobuhiro
    Matsunaga, Kotaro
    Watanabe, Tsunemasa
    Uojima, Haruki
    Hidaka, Hisashi
    Kusano, Chika
    Morimoto, Manabu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [46] Development and validation of a deep learning model for survival prognosis of transcatheter arterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma
    Wang, Hairui
    Liu, Yuchan
    Xu, Nan
    Sun, Yuanyuan
    Fu, Shihan
    Wu, Yunuo
    Liu, Chunhe
    Cui, Lei
    Liu, Zhaoyu
    Chang, Zhihui
    Li, Shu
    Deng, Kexue
    Song, Jiangdian
    EUROPEAN JOURNAL OF RADIOLOGY, 2022, 156
  • [47] Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Michitaka, Kojiro
    Atsukawa, Masanori
    Hirooka, Masashi
    Tsuji, Kunihiko
    Ishikawa, Toru
    Takaguchi, Koichi
    Kariyama, Kazuya
    Itobayashi, Ei
    Tajiri, Kazuto
    Shimada, Noritomo
    Shibata, Hiroshi
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Fukunishi, Shinya
    Ohama, Hideko
    Kawata, Kazuhito
    Nakamura, Shinichiro
    Nouso, Kazuhiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Joko, Kouji
    Koizumi, Yohei
    Hiasa, Yoichi
    ONCOLOGY, 2021, 99 (08) : 518 - 527
  • [48] New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
    Masatoshi Kudo
    International Journal of Clinical Oncology, 2022, 27 : 1110 - 1119
  • [49] Management of Intermediate-Stage Hepatocellular Carcinoma: Systemic Versus Locoregional Therapy
    Patel, Mikin
    Pillai, Anjana
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 33 (01) : 159 - 172
  • [50] Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
    Zhou, Qunfang
    Tuo, Fei
    Li, Ruixia
    Wang, Xiaohui
    Wang, Juncheng
    Huang, Zhimei
    Chen, Minshan
    Huang, Jinhua
    FRONTIERS IN ONCOLOGY, 2020, 10